Tucatinib,Trastuzumab
seagen
new today at #wcgic2022: full results from our pivotal phase 2 trial in her2-positive metastatic #colorectalcancer.
Official Twitter for Seagen. Global biotechnology company focused on transformative cancer medicines to improve lives. Guidelines https://t.co/mK6wXiXw22